ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference

ANI Pharmaceuticals' CEO will present at the J.P. Morgan Healthcare Conference on January 13, 2026, with a webcast available.

Quiver AI Summary

ANI Pharmaceuticals, Inc. has announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The presentation will be available via live and archived webcast on the company's website, with the replay accessible for 30 days. ANI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics, particularly in rare diseases, as well as generics and brand products, with a commitment to improving patient lives. For further details, they provide contact information for investor and media relations.

Potential Positives

ANI Pharmaceuticals is participating in the prestigious 44th Annual J.P. Morgan Healthcare Conference, which enhances its visibility and credibility in the healthcare sector.
The presentation by CEO Nikhil Lalwani at a notable industry event highlights leadership engagement and the company's commitment to communicating its strategies to investors and stakeholders.
The webcast availability for live and archived viewing allows for broader accessibility, catering to a wider investor audience and facilitating ongoing engagement with the company's developments.
ANI Pharmaceuticals delineates its focus on sustainable growth through its diverse business segments, which may appeal to investors looking for stability and innovation in their portfolios.

Potential Negatives

The press release does not provide any new or impactful information beyond the details of the conference presentation, which could suggest a lack of significant developments or updates concerning the company's operations or financial performance.
There is no mention of recent financial performance or forecasts, which could indicate potential underlying issues or a lack of transparency regarding the company's health.
The focus on the upcoming conference rather than substantial news could reflect a reliance on public engagements for positive perception rather than tangible progress in the business.

FAQ

When is ANI Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

ANI Pharmaceuticals will present on January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.

Where can I watch the ANI Pharmaceuticals presentation?

The presentation can be viewed live and archived on the ANI Pharmaceuticals website under the Investors section.

How long will the webcast be available for replay?

The replay of the webcast will be accessible for 30 days after the presentation.

What are ANI Pharmaceuticals' business focuses?

ANI Pharmaceuticals focuses on Rare Disease, Generics, and Brands in its biopharmaceutical operations.

Who should I contact for investor relations at ANI Pharmaceuticals?

For investor relations, contact Courtney Mogerley at Argot Partners via email at [email protected].

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ANIP Insider Trading Activity

$ANIP insiders have traded $ANIP stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:

MUTHUSAMY SHANMUGAM (HEAD OF R&D, COO-NOVITIUM OPS) has made 0 purchases and 4 sales selling 200,000 shares for an estimated $17,860,541.
NIKHIL LALWANI (PRESIDENT & CEO) sold 56,960 shares for an estimated $4,894,572
STEPHEN P. CAREY (SVP & CFO) sold 50,000 shares for an estimated $4,303,500
CHAD GASSERT (SVP - CORP. DEV. & STRATEGY) has made 0 purchases and 3 sales selling 34,736 shares for an estimated $3,051,834.
JEANNE THOMA has made 0 purchases and 2 sales selling 21,540 shares for an estimated $1,920,369.
THOMAS HAUGHEY sold 19,341 shares for an estimated $1,661,972
PATRICK D WALSH has made 0 purchases and 2 sales selling 17,643 shares for an estimated $1,552,353.
ANTONIO R PERA has made 0 purchases and 2 sales selling 12,713 shares for an estimated $1,178,728.
MATTHEW J LEONARD has made 0 purchases and 2 sales selling 9,465 shares for an estimated $840,722.
ORI GUTWERG (SVP, GENERICS) sold 5,873 shares for an estimated $508,190
THOMAS ANDREW ROWLAND (SVP, HEAD - ESTABLISHED BRANDS) sold 4,975 shares for an estimated $426,407
KRISTA DAVIS (SVP, CHIEF HR OFFICER) has made 0 purchases and 3 sales selling 4,385 shares for an estimated $392,302.
MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has made 0 purchases and 6 sales selling 2,400 shares for an estimated $204,740.
RENEE P TANNENBAUM sold 1,800 shares for an estimated $146,070

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ANIP Revenue

$ANIP had revenues of $227.8M in Q3 2025. This is an increase of 53.58% from the same period in the prior year.

You can track ANIP financials on Quiver Quantitative's ANIP stock page.

$ANIP Hedge Fund Activity

We have seen 142 institutional investors add shares of $ANIP stock to their portfolio, and 107 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 938,631 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $85,978,599
POINT72 ASSET MANAGEMENT, L.P. added 399,092 shares (+inf%) to their portfolio in Q3 2025, for an estimated $36,556,827
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 360,178 shares (+inf%) to their portfolio in Q3 2025, for an estimated $32,992,304
SOLEUS CAPITAL MANAGEMENT, L.P. added 289,500 shares (+570.5%) to their portfolio in Q3 2025, for an estimated $26,518,200
BALYASNY ASSET MANAGEMENT L.P. added 276,233 shares (+2785.7%) to their portfolio in Q3 2025, for an estimated $25,302,942
RANGER INVESTMENT MANAGEMENT, L.P. removed 262,888 shares (-49.2%) from their portfolio in Q3 2025, for an estimated $24,080,540
DEEP TRACK CAPITAL, LP removed 250,000 shares (-35.7%) from their portfolio in Q3 2025, for an estimated $22,900,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ANIP Analyst Ratings

Wall Street analysts have issued reports on $ANIP in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 11/10/2025
JP Morgan issued a "Overweight" rating on 09/24/2025
HC Wainwright & Co. issued a "Buy" rating on 09/17/2025

To track analyst ratings and price targets for $ANIP, check out Quiver Quantitative's $ANIP forecast page.

$ANIP Price Targets

Multiple analysts have issued price targets for $ANIP recently. We have seen 5 analysts offer price targets for $ANIP in the last 6 months, with a median target of $115.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $100.0 on 12/09/2025
Vamil Divan from Guggenheim set a target price of $115.0 on 11/10/2025
Gregory Fraser from Truist Securities set a target price of $90.0 on 10/09/2025
Ekaterina Knyazkova from JP Morgan set a target price of $115.0 on 09/24/2025
Brandon Folkes from HC Wainwright & Co. set a target price of $121.0 on 09/17/2025

Full Release

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44 ^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.

The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 30 days.

About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com .

Investor Relations:
Courtney Mogerley, Argot Partners
E: [email protected]

Media Relations:
Deborah Elson, Argot Partners
E: [email protected]